ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel

Back

ESC Professional Premium Access

ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel

Session: Cancer and other risk factors for heart disease

Topic: Biomarkers

Speaker: Doctor J. Li (Beijing, CN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Jiawen Li

Beijing (China)

1 presentation

0 follower

7 more presentations in this session

Ischemic and bleeding risk after ST-segment elevated myocardial infarction in patients with active cancer

Speaker: Doctor M. Dafaalla (Keele, GB)

External validation of the Systematic COronary Risk Evaluation 2 (SCORE2) model in cancer patients

Speaker: Mrs M. Gynnild (Trondheim, NO)

Comparison of cardiovascular disease risk assessment tools for heart failure prediction among cancer patients

Speaker: Professor T. Marwick (Melbourne, AU)

Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors

Speaker: Professor T. Marwick (Melbourne, AU)

Long-term prognostic impact of fasting plasma glucose and myocardial flow reserve beyond other risk factors and heart disease phenotypes

Speaker: Doctor D. Neglia (Pisa, IT)

Access the full session

Cancer and other risk factors for heart disease

Speakers: Doctor J. Li, Doctor M. Dafaalla, Mrs M. Gynnild, Professor T. Marwick, Professor T. Marwick...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources